Morgan Stanley on Pfizer (PFE): 'we believe generic versions of Vyndaqel could still represent a potential headwind to the franchise'
Tweet Send to a Friend
Morgan Stanley analyst Terence Flynn reiterated an Equalweight rating and $28.00 price target on Pfizer (NYSE: PFE).The analyst comments "PFE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
